(Q40288223)

19 September 2017

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. (English)

1 reference

19 September 2017

L Ma

1

1 reference

19 September 2017

J R Clayton

2

1 reference

19 September 2017

R A Walgren

3

1 reference

19 September 2017

B Zhao

4

1 reference

19 September 2017

R J Evans

5

1 reference

19 September 2017

M C Smith

6

1 reference

19 September 2017

K M Heinz-Taheny

7

1 reference

19 September 2017

E L Kreklau

8

1 reference

19 September 2017

L Bloem

9

1 reference

19 September 2017

C Pitou

10

1 reference

19 September 2017

W Shen

11

1 reference

19 September 2017

J M Strelow

12

1 reference

19 September 2017

C Halstead

13

1 reference

19 September 2017

M E Rempala

14

1 reference

19 September 2017

S Parthasarathy

15

1 reference

19 September 2017

J R Gillig

16

1 reference

19 September 2017

L J Heinz

17

1 reference

19 September 2017

H Pei

18

1 reference

19 September 2017

Y Wang

19

1 reference

19 September 2017

L F Stancato

20

1 reference

19 September 2017

M S Dowless

21

1 reference

19 September 2017

P W Iversen

22

1 reference

19 September 2017

T P Burkholder

23

1 reference

19 September 2017

12 April 2013

1 reference

19 September 2017

1 reference

19 September 2017

3

1 reference

19 September 2017

e109

1 reference

https://scigraph.springernature.com/pub.10.1038/bcj.2013.6

19 September 2017

0 references

cites work

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Characterization of murine JAK2V617F-positive myeloproliferative disease

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Identification of an acquired JAK2 mutation in polycythemia vera

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

A gain-of-function mutation of JAK2 in myeloproliferative disorders

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

The Erythropoietin Receptor: Structure, Activation and Intracellular Signal Transduction.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Characteristics of indirect pharmacodynamic models and applications to clinical drug responses

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Letter: Bone-marrow responses in polycythemia vera

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3641321

Geometrical reaction coordinates. II. Nucleophilic addition to a carbonyl group

20 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBCJ.2013.6

The myeloproliferative disorder associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBCJ.2013.6

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23584399

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BCJ.2013.6

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference

19 September 2017

PubMed publication ID

23584399

1 reference